• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Diabetes News
Abstract More than 31,000 attendeesfrom around the world gathered in Barcelona, Spain for the 2017 European Society of Cardiology conference. In presentinga post‐hoc analysis of the Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes(LEADER)1 trial, Dr Neil Poulter (Imperial College London, UK) showedthat results are still positive, indicating cardioprotection, after adjusting for baseline history of stroke or myocardial infarction (MI), which had no mediating effect on the significant association between Novo Nordisk's (Copenhagen, Denmark) glucagon‐like peptide‐1 (GLP‐1) agonist Victoza (liraglutide) and c...
Source: Journal of Diabetes - September 1, 2017 Category: Endocrinology Authors: Ann M. Carracher, Payal H. Marathe, Kelly L. Close Tags: News Source Type: research